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Abstract 
Background: Therapeutic drug monitoring (TDM) of Vancomycin (VCM) is required to prevent inappropriate dosage-
associated bacterial resistance, therapeutic failure, and toxicities in pediatrics. Anecdotal experience and studies show 
that many healthcare institutions confront barriers while implementing TDM services, this study aimed to assess a 
pharmacist-directed VCM–TDM service for optimizing patient care in our institution.
Materials and methods: Patients aged 1 month–18 years who received intravenous VCM were included in this 
quasi-experimental study. The pre-implementation phase (March–June 2018) consisted of retrospective assessment 
of pediatric patients, the interventional phase (July 2018 to February 2020) included educational programs and the 
post-implementation phase (March–June 2020) evaluated the participants based on pharmacist-directed VCM–TDM 
services as a collaborative-practice model including clinical and inpatient pharmacists to provide 24/7 TDM ser-
vices. Outcomes of the study included the mean difference in the number of optimal (i) prescribed initial VCM doses 
(primary) (ii) dosage adjustments and (iii) VCM-sampling time (secondary). After ethical approval, data were collected 
retrospectively.
Results: A hundred patients were there in each phase. The number of cases who were correctly prescribed initial 
VCM doses was significantly higher in the post-implementation phase, mean difference of 0.22, [95% CI (0.142–
0.0.358), p < 0.0001]. Patients who had correct dosage adjustments in the post-implementation phase also had higher 
statistical significance, mean difference of 0.29, [95% CI (0.152–0.423), p < 0.05]. More correct practices of VCM-levels 
timing were observed in the post-implementation phase, mean difference of 0.15, [95% CI (− 0.053–0.264), p = 0.079].
Conclusion: This study showed the significant role of pharmacist-directed TDM services to optimize the correct 
prescribing of initial VCM doses and dose adjustments.
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Introduction
Therapeutic drug monitoring (TDM) is the core respon-
sibility of pharmacists for the delivery of optimum ther-
apy to patients [1]. It is defined as the measure of blood 
concentrations of specific drugs at specified times for 
maintaining the concentration at steady-state and sub-
sequently helps in individualizing the drug doses for the 
attainment of therapeutic targets [1, 2]. Aminoglycosides 
and vancomycin are the most monitored drugs espe-
cially in pediatric patients [3, 4]. Pharmacist-led TDM is 
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reported to have positive patient outcomes including a 
reduced number of adverse drug effects (ADRs), shorten 
duration of therapy and hospital stay, lower rates of mor-
bidity and mortality, and reduce the cost of therapy [1–3, 
5–7]. Practically these patient-centered benefits can be 
achievable with the optimal utilization of pharmacists in 
healthcare settings [6, 8]. However, strong knowledge of 
the pharmacist about the pharmacokinetics (PK) prin-
ciples and their practical implementation is required for 
effective TDM services [6].
In Pakistan, there is no published data about the assess-
ment of hospital pharmacy TDM services and their effect 
on patient outcomes. However, a recently published 
Asian study reported that about 41% of hospitals in 
Riyadh, Saudi Arabia, engage their pharmacists in TDM 
activity and evaluate patient outcomes and recommend 
changes where needed [9]. The reported contribution of 
pharmacists is significantly lower than the rate reported 
in a 2010 survey by the American Society of Health-Sys-
tem Pharmacists (ASHP), where > 92% of American hos-
pitals involved pharmacists for TDM [9, 10].
Medications PK monitoring-associated pharmacist 
responsibilities are established by ASHP [1]. Though, 
according to the current practices in our hospital phar-
macists perform only a few of them, while working clini-
cally and as an inpatient pharmacists. In the children’s 
units of the Aga Khan University Hospital, clinical phar-
macists round with the physician team on weekdays in 
day shift, deliver TDM services, and routinely follow-up 
all the patients in pediatric and neonatal intensive care 
units (NICU and PICU), pediatric cardiac intensive care 
units (PCICU), and all pediatric special care and oncol-
ogy units. In addition, pharmacist-based vancomy-
cin TDM is provided to all admitted patients through 
extracting the data of all the patients on vancomycin 
therapy on daily basis by a dedicated pharmacist. Unlike 
other hospitals pharmacists in AKUH are not consulted 
for this activity but they are assigned to perform this 
task routinely [11]. All the newly hired pharmacists are 
trained for performing TDM activity during the train-
ing period and mentor-guided competencies of inpa-
tient pharmacists are enhanced through educational 
lectures, supported by the provision of screening check-
lists and flowcharts [12] and finally evaluated before task 
assignments.
This study aimed to evaluate the impact of the collab-
orative-practice model, through implementing dedicated 
pharmacist directed-TDM services in combination/addi-
tion to the clinical pharmacist, and inpatient pharmacist 
to advance the vancomycin TDM and to overcome the 
barriers through the enhancement of pharmacist knowl-
edge and skills regarding vancomycin TDM and provid-
ing vancomycin TDM focused 24/7 services for optimal 
patient care for hospitalized pediatric patients through 
the collaborative-practice model.
Materials and methods
Study design, settings, and duration
The impact of the implementation of pharmacist-directed 
vancomycin therapeutic drug monitoring as a collabora-
tive-practice model on predefined outcome measures 
was evaluated in the pediatric units of Aga khan univer-
sity hospital (AKUH), a teaching tertiary care hospital in 
Karachi, Pakistan, and associated with Aga Khan Univer-
sity. The study was performed after the approval of the 
institutional Ethical Review Committee (ERC) and the 
need for written informed consent was waived for retro-
spectively collected patients’ data.
We designed a single-center quasi-experimental study 
and compared 3  months (March–June 2018) of pre-
implementation data with 3 months (March–June 2020) 
of post-implementation data. With implementation/
training phase from July 2018 to February 2020. During 
this phase, all the standard operating procedures (SOPs) 
for pharmacist-directed VCM–TDM services were 
designed, and training was completed involving clinical, 
inpatients, and TDM-assigned pharmacists.
Study population and sample size
In the present study pediatric patients of age > 30  days 
and less than 18 years were involved, who were admitted 
under the medical care in AKUH, either in the general 
ward or pediatric intensive care units (PICU & PCICU), 
and treated with intravenous VCM for suspected or con-
firmed infections during the specified study duration. 
All the pediatric patients admitted under the medical 
care were screened for inclusion, as ideally, all patients 
on VCM therapy need to be monitored for blood level. 
However, for all the pediatric cases who were exposed to 
multiple courses of VCM therapy during pre- and post-
phases of study, only the first course of VCM exposure 
was included in data analysis. Patients who received only 
24–72 h of empiric VCM therapy, were also included, as 
VCM trough levels are required before the 4th schedule 
dose at a steady state [13]. We excluded all the patients 
who started antibiotic therapy prior to hospital admis-
sion and information about the therapy start time, sam-
ple collection time, and trough values were missing. 
Patients who received VCM post cardiothoracic surgery, 
who had congenital heart diseases (CHD), congenital 
anomalies, and febrile neutropenia were also excluded. 
The sample size was estimated of 100 participants in each 
group to give a 90% power to identify a difference of 21% 
in pre and post-intervention phases for the frequency 
of prescribing correct initial doses of vancomycin [7] at 
95% CI using PASS version 11. Patients were included by 
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convenience sampling from the list of all eligible cases 
provided by the Information Technology (IT) dept.
Clinical and inpatient pharmacists’ activities
In AKUH, clinical pharmacists are performing clinical 
activities by attending daily ward rounds with the physi-
cian teams and recommend drug interventions for opti-
mization of therapy with effective follow-ups to monitor 
the patients for the attainment of targeted therapeutic 
outcomes. In addition, under the direction of the man-
ager of clinical pharmacy, clinical pharmacists perform 
a number of other drug-related responsibilities such as 
monitoring and reporting medication-safety through 
reporting adverse drug reactions (ADRs), participate in 
developing drug protocols, providing medication recon-
ciliation and counseling, running antibiotic stewardship 
program, and participating as active members in the anti-
biotic subcommittee, etc. Clinical pharmacists are also 
contributing to clinical research and training pharmacy 
interns, new pharmacists, physicians, and nurses. Never-
theless, they are not assigned to verify the electronically 
prescribed physicians’ medication orders. Conversely, 
inpatient pharmacists assigned as in-charge in pharma-
cies are primarily responsible for electronic verification 
of physicians’ orders. In our hospital, physicians place 
medication orders through computerized physician order 
entry (CPOE) for all the hospitalized patients and these 
orders are verified and processed by the inpatient phar-
macists through CPOE. They do not participate in daily 
ward rounds and are not responsible for patient follow-
up for the achievement of desired therapeutic goals.
Implementation of pharmacist‑directed vancomycin TDM
The project comprised of Pre-pharmacist directed-TDM 
phase (pre-PD-TDM-phase), intervention-phase, and 
post-pharmacist directed-TDM phase (post-PD-TDM-
phase). In the pre-PD-TDM-phase of 3 months, the study 
pharmacist assessed all the eligible patients retrospec-
tively. In the intervention phase, the manager clinical 
pharmacy designed the VCM TDM educational sessions 
for all pharmacists, involved antibiotic subcommittee 
and P & TC members for the approval of this activity by 
pharmacists, and highlighted the importance of this pro-
spective audit and interventional activity for the achieve-
ment of clinical outcomes. Then involved all the clinical 
and inpatient pharmacists and provided vancomycin PK-
based interactive sessions in the period of about one and 
half years to cover all the on-board inpatients and clinical 
pharmacists. For the frontline pharmacist convenience 
and learning, pharmacists were equipped with age-based 
dosing and monitoring checklist and flowcharts of VCM 
regimens. P & TC approved AKUH antibiotic guide-
lines are developed in accordance with the ASHP/IDSA 
guidelines [14] and drug monographs. These guideline-
based sessions were also included, and a pocket copy 
was also provided to each participant. Participants were 
assessed initially through assessment questions. Before 
and after each session’s test was conducted to assess the 
pharmacist’s knowledge. Based on assessment results 
pharmacists were assigned vancomycin TDM activity. 
Role of clinical and inpatient pharmacist defined in this 
collaborative model under the direct supervision and 
direction of manager clinical pharmacy. Pharmacists 
were further assessed for the execution of their knowl-
edge and skills during this period.
In the post-PD-TDM phase, the assigned TDM-phar-
macist got fully involved in the provision of vancomy-
cin–TDM services and daily applied a system-based filter 
to get the drug charts data of all the patients on VCM to 
review the appropriateness of therapy and drug levels 
ordering. This pharmacist communicates with the physi-
cian team through a call for the communication of dose 
optimization and level ordering. In addition, pharmacist 
directed-TDM services also involved the provision of 
information and recommendation to the primary care 
doctors’ team, infectious disease physicians, and clinical 
pharmacists about the vancomycin initial dosing regi-
men, dosing adjustments, and serum blood concentration 
requests. Clinical pharmacists also covered all the pediat-
ric patients during clinical pharmacist rounds (including 
PICU, PCICU, pediatric special care, and oncology units) 
for TDM services. These both pharmacists were available 
during day shifts and on weekdays only. All the pending 
follow-ups for dose adjustments and levels ordering were 
carried out by the inpatient pharmacists, who give 24/7 
service.
Data collection
Data of all demographic and clinical variables were col-
lected retrospectively. Date of the correctness of initial 
VCM doses, dose adjustments, ordering time, all the 
therapeutic interventions, communications, follow-ups, 
laboratory results, and approvals was maintained in an 
excel sheet and shared with clinical pharmacy manage on 
daily basis, who also facilitate the communication among 
all TDM-pharmacists, clinical and inpatient pharmacists 
around the schedule.
Outcome measures
The primary outcome of the study was to assess the 
influence of pharmacist-directed TDM intervention on 
the frequency of prescribing the correct initial dose of 
vancomycin in pediatric patients as per institutional 
antibiotic guidelines by comparing pre- and post-inter-
vention phases. This study had secondary outcomes 
including the evaluation of difference in the proportion 
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of dosing correction/adjustment within 8 h (same phar-
macist shift) and optimal blood sampling time prac-
tices. The drug levels orders were defined optimal if the 
sample drawing time for the initial trough levels of van-
comycin is within 1 h before the scheduled time of the 
4th dose administration [13].
Statistical analysis
Statistical analysis was run using STATA version 15 
(STATA Corp, Texas). The baseline characteristics of 
the study participants, orders of initial vancomycin 
dosages, dose adjustments, and blood sampling times 
were described and reported by descriptive statistics. 
We used Fischer’s exact and χ2 tests if found cells count 
of ≤ 5 for categorical and binary variables. The non-
normally distributed continuous baseline variables 
were compared by Mann–Whitney test. A two-sample 
test of proportion was applied to evaluate proportions 
mean difference and 95% CI for the orders of VCM-
initial dosages, dose adjustments, and blood sampling 
times. We used two-sided tests and a p value < 0.05 and 
95% confidence interval (CI) were deemed statistically 
significant.
Ethical approval
Before performing this study, ethical approval was taken 
from the institutional ethical committee of Aga Khan 
University Hospital (ERC # 2020-5150-11,679).
Results
In this study, we screened a total of 1650 pediatric 
patients for eligibility, 756 and 799 cases in the pre–
post-implementation phases, respectively, from the 100 
cases were enrolled in each phase of the study (Fig.  1). 
The baseline demographic and clinical characteristics of 
both groups were comparable. Male participants were 
higher in both phases. We further divided the patients 
into five age groups, including Group-I: (1–6  months), 
Group-II: (6  months–2  years), Group-III: (2–6  years), 
Group-IV: (6–12 years), and Group-V: (12–18 years). In 
both phases, the highest proportion of children were of 
2–6  years of age (Group-III) who received intravenous 
vancomycin therapy. A substantial proportion of patients 
were started vancomycin therapy in the emergency 
department in both phases (Table  1). A significantly 
higher number of patients were prescribed optimal ini-
tial vancomycin doses in the pharmacist-directed TDM 
phase compared to the pre-phase of the study (96% vs. 
Pre-Pharmacist directed-TDM phase Post-Pharmacist directed-TDM phase
832 pediatric paents were screened 
Excluded based on 
Age < 30 days                                         112
Febrile neutropenia                              33
Congenital anomalies                           15
Surgical prophylaxis                              45
Received VCM therapy for ≤ 2days 316
Iniated VCM prior to admission 211  
100 Pediatric paents analysed  100  Pediatric paents analysed  
Excluded based on 
Age < 30 days and > 18 years             109
Febrile neutropenia                              39
Congenital anomalies                           13
Surgical prophylaxis                              56
Received VCM therapy for ≤ 2days 312
Iniated VCM prior to admission 200  
829 pediatric paents were screened 
Fig. 1 Patient inclusion scheme
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45%). However, from secondary outcomes, we found 
significant improvement in optimal doses adjustment 
(50.6% in pre-phase vs. 88.8% in post-phase). Optimal 
vancomycin levels request improved in post-phase, but 
it was not statistically significant (37.6% in pre-phase vs. 
58.9% in post-phase) (Table 2).
Most of the incorrectly prescribed initial vancomycin 
doses and adjusted doses were sub-therapeutic in both 
the study phases (Fig.  2). Data analysis of numbers of 
incorrectly ordered VCM levels shows that wrong level 
time prescribed by the physician was the most common 
reason for incorrect VCM levels (70 in pre-phase vs. 51 
in post-phase) (Fig. 3).
The duration of vancomycin therapy was shorter in 
the post-implementation phase than the pre-imple-
mentation phase of the study [median of 8 days; Inter-
quartile range (IQR: 6–15) vs. 11  days; (IQR: 8–16), 
(p = 0.078)].
Table 1 Baseline demographic and laboratory characteristics of study participants in both phases
Data presented as n (%) or Median; IQR. Abbreviations: TDM, therapeutic drug monitoring; VCM, vancomycin; PICU, pediatric intensive care unit; NICU, neonatal 
intensive care unit; UTI, urinary tract infection; acalculation based on Schwartz equation formula
Variables Pre‑pharmacist directed‑TDM phase 
(n = 100)
Post‑pharmacist directed‑TDM 
phase (n = 100)
p value
Age
 Group-I: children of age 1–6 months 22 (22.0%) 19 (19.0%) 0.895
 Group-II: children of > 6 months–2 years 14 (14.0%) 16 (16.0%) 0.887
 Group-III: children of > 2–6 years 47 (47.0%) 51 (51.0%) 0.765
 Group-IV: children of > 6–12 years 9 (9.0%) 8 (8.0%) 0.998
 Group-V: children > 12–18 years 8 (8.0%) 6 (6.0%) 0.958
Sex (male) 61 (61.0%) 59 (59.0%) 0.988
Units of the hospital where VCM therapy initiated
 Emergency 31 (31.0%) 44 (44.0%) 0.075
 PICU 11 (11.0%) 10 (10.0%) 0.899
 Medicine 21 (21.0%) 18 (18.0%) 0.682
 NICU 19 (19.0%) 16 (16.0%) 0.618
 Surgery 18 (18.0%) 12 (12.0%) 0.061
Indications of VCM use
 UTI 9 (9%) 7 (7.0%) 0.895
 Meningitis 12 (12.0%) 10 (10.0%) 0.956
 Endocarditis 2 (2.0%) 1 (1.0%) 0.978
 Skin and soft tissue infections 8 (8.0%) 10 (10.0%) 0.959
 Bacteraemia 33 (33.0%) 36 (36.0%) 0.897
 Pneumonia 28 (28.0%) 27 (27.0%) 0.964
 Osteomyelitis 3 (3.0%) 2 (2.0%) 0.785
 Intra-abdominal infections 5 (5.0%) 7 (7.0%) 0.823
Baseline laboratory values at VCM initiation
 Creatinine clearance (ml/min)a 72.5 (15.5–98.5) 68.9 (10.8–97.2) 0.391
 While blood counts (×  109 Cells/L) 10.2 (6.9–15.9) 10.8 (7.1–16.0) 0.699
Patients with impaired renal function 19 (%) 22 (%) 0.119
Table 2 Comparison of study outcomes in pre and post-implementation phases




Mean difference (95% CI) p value
Optimum prescribed initial VCM doses 45.0% (45/100) 96% (96/100) 0.22 (0.14–0.36)  < 0.0001
Optimum VCM-dosage adjustments 50.6% (83/164) 88.8% (95/107) 0.29 (0.15–0.42)  < 0.05
Optimum VCM-sampling time 37.6% (82/218) 58.9% (168/285) 0.15 (− 0.05–0.26) 0.079
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Discussion
Therapeutic drug monitoring (TDM) practices are 
reported to result in the better clinical efficacy of 
concentration-dependent medications through the 
improved likelihood of targeted blood levels achieve-
ment [14]. Like previous studies, our study also shows 
the significant benefit of the implementation of phar-
macist-directed TDM practices in terms of a higher 
number of patients dosed with optimal initial vanco-
mycin doses, optimal dosage adjustments in a timely 
manner, and ordering vancomycin trough levels at the 
correct time [7, 11]. Comparatively better results are 
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Pre-Pharmacist directed-TDM phase Post-Pharmacist directed-TDM phase
Fig. 3 Proportion of incorrect vancomycin serum levels orders
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to the implementation of a collaborative pharmacy 
practice model instead of isolated efforts.
Alhameed et  al. [11] reported significantly improved 
prescribing of correct initial vancomycin doses through 
pharmacist-directed TDM services, which raised the bar 
of correct initial doses from 60 to 91%. However, Mar-
quis et al. [7] studied the pharmacist-led TDM effect on 
optimal prescribing of vancomycin initial dosing within 
24 h and reported a 50% improvement. As a recent study, 
in the present study, we evaluated entire TDM services 
as involving optimal initial dose, following dose and fre-
quency adjustments, and vancomycin trough levels, 
which are important segments of this service to main-
tain the continuity of care and to attain desired clinical 
results for patients [11]. Most of the patients prescribed 
vancomycin need timely achievement of targeted trough 
levels, which need earlier adjustments of vancomycin 
dose orders. Therefore, in this study, we considered the 
prescription order correct if adjusted within 8 h vs. 24 h 
in the previous study [7]. The selection of a narrow inter-
val for dose adjustments in our study helped us in high-
lighting and involving inpatient pharmacist importance 
in TDM processes by their interventions in the absence 
of clinical pharmacists. Marquis et al. [7] reported 40.4% 
optimal vancomycin orders within 24 h vs. 75.5% in our 
study. In addition, Alhameed et al. [11] also selected 8 h’ 
time interval and reported 60% correct orders within 8 h 
in their setting. This difference in results can be explained 
by the consolidated approach of involving all the phar-
macists’ teams to provide 24/7 TDM services with strong 
supervision and directions.
The effect of computerized physician order entry 
(CPOE) had been evaluated in previous studies and 
reported a moderate effect on vancomycin TDM ser-
vices [15, 16]. In Damfu et  al. [16] study the selected 
population was only surgical patients, and CPOE oper-
ation-oriented educational sessions were conducted for 
the residents’ teams, responsible for vancomycin order 
entry. Their study did not involve clinical pharmacists in 
TDM services. On the other hand, in our setting CPOE is 
already implemented. In addition, in our study not only 
the target population was different but also involved the 
clinical and inpatient pharmacist with dedicated TDM 
pharmacist. This multidirectional approach in our study 
resulted in a higher proportion of appropriate initial 
vancomycin orders. More or less the same results have 
been reported in another study, where the almost same 
approach was adopted [11], which shown that the com-
bination of computerized physician order entry use with 
pharmacist-directed TDM service can be more effective 
in achieving targeted therapeutic goals.
For the optimal initial dose prescribing, we 
achieved statistically significant improvement in the 
pharmacist-directed TDM phase, which we can also cor-
relate with the more focused approach of the pharmacist 
for appropriateness of the vancomycin doses through 
careful assessment of all clinical parameters of the 
patients receiving vancomycin for the first time. Regard-
ing optimal dosage adjustments, we also found statisti-
cally significant improvement in the pharmacist-directed 
TDM-phase compared to the pre-phase. Our results are 
different than a recently published study, as they reported 
statistically insignificant improvement in optimal dosage 
adjustments [11]. Although, Alhameed et al. also adopted 
the same approach but shared the lack of pharmacist 
timely follow-up as the major contributing factor for 
insignificant improvement [11]. However, in our setting 
pharmacist-directed vancomycin TDM services are per-
formed by the dedicated TDM-pharmacist, clinical phar-
macist (doing round with physician team), and inpatient 
pharmacist (who verify each vancomycin order even for 
renal adjustments). Top of all the communication among 
the pharmacist’s team and physicians can play a signifi-
cant role for the timely dose adjustments.
In terms of optimal vancomycin levels, we found an 
influential finding that more vancomycin level orders 
were requested in the pharmacist-directed TDM-phase 
than in the pre-phase. In addition, we also found that 
the number of unnecessarily ordered drug levels also 
increased in the post-phase compared to pre-phase. This 
is most likely because drug levels orders are placed by the 
physician, who is more aware of the significance of van-
comycin levels but not for the pharmacokinetic-based 
sampling frequencies and time in pediatric patients [13]. 
Consequently, leading to additional level orders may be 
on the request of the pharmacy team to get the accu-
rate blood concentrations. This wastage of resources and 
extra cost can be curtailed through the physician and 
nurses’ educational sessions about proper sampling time 
and frequency for vancomycin during the implementa-
tion phase. The empowerment of the pharmacist to place 
an order for vancomycin levels can be the most cost-
effective and efficient option.
This study has few limitations, including; it is a sin-
gle cantered study of limited study period and gener-
alizability. The quasi-experimental study design has the 
potential for confounding bias. Although, there was 
no significant difference in study participants’ demo-
graphic and clinical characteristics in both phases. 
However, variations in unmeasured variables may be 
present between the groups. Study design associated 
bias, such as instrumentation and maturation, because 
of the difference amongst the inpatient pharmacists’ 
skills in pre and post-phases, which might influence the 
internal validity. While processing the order in CPOE 
inpatient pharmacists cannot modify the prescribed 
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medication order unless approved/modified by the 
physician in CPOE, which might have undervalued the 
appropriate order recommended by TDM and clinical 
pharmacists for vancomycin regimen optimization if 
the prescribing physician did not accept it or respond 
to inpatient pharmacist’s call. Since drug levels orders 
are not medication orders, the pharmacist does not get 
any notification of these orders, therefore, cannot can-
cel or correct the inappropriately ordered vancomycin 
levels.
Our study has many strengths. First, participation of 
a big number of trained pharmacists and subsequent 
optimal dose adjustments with effective following-ups 
through robust team communication gave a strong 
impact on pharmacist-directed TDM services through a 
collaborative practice model. We were capable of engag-
ing inpatient pharmacists in patient-centered pharmacist-
directed clinical TDM services. The quasi-experimental 
study design is also a big strength of the study, for assess-
ing the practices change in the post-intervention phase. 
We could study the whole pharmacist-directed TDM ser-
vices by assessing three main components. To our knowl-
edge, this is the first study in Pakistan to measure the 
impact of pharmacist-directed VCM therapeutic drug 
monitoring in the pediatric population.
The focus of future investigations shall be on exploring 
the impact of the implementation of computerized physi-
cian order entry, pharmacist-directed TDM services, and 
educational intervention of physicians and nurses collec-
tively, to evaluate the results of applying multidepartment 
collaborative-practice model which provides empower-
ment to TDM directing pharmacists for complete TDM 
rights, including drug regimen modifications for optimi-
zation and level ordering authority.
Conclusions
This study establishes the significance of a pharmacist-
directed TDM service, which had a positive impact on 
vancomycin optimal initial dose prescribing and effi-
cient dose adjustments in pediatric patients. However, 
the result of this study highlights the need for future 
studies to investigate the opportunities for pharmacy-
practices models, which can address the barriers to jus-
tified drug levels ordering mechanism in TDM services.
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